Live Breaking News & Updates on Leukocyte Removal Filters|Page 1

Published: Feb 24, 2021
 
Joint Venture Will Enable Cerus to Partner with Leader in Transfusion Medicine to Bring INTERCEPT to the Mainland China Transfusion Market
 
CONCORD, Calif. (BUSINESS WIRE) Cerus Corporation (Nasdaq: CERS) and Shandong Zhongbaokang Medical Implements Co. Ltd. (ZBK) today announced that they are forming a joint venture (JV) with the intent to develop, obtain regulatory approval for, manufacture and commercialize the INTERCEPT Blood System for platelets and red blood cells in China. The JV, which will be named “Cerus ZBK Biomedical” (CEZB), will be headquartered in Zibo, Shandong Province in eastern China.
“We are honored to join forces with ZBK in China, furthering our mission to make INTERCEPT the standard of care for patients globally,” said Pascal Maillard, Cerus’ vice president of commercial operations for the Asia Pacific region. “We believe that ZBK’s experience with local clinical and regulatory requirements ....

United States , Xu Junfeng , Pascal Maillard , Exchange Commission , Cerus Corporation , Shandong Zhongbaokang Medical Implements Co , Cerus Corporation Nasdaq , Shandong Zhongbaokang Medical Implements Co Ltd , Taibao Group , Shandong Zhongbaokang Medical Implements , Shandong Province , Asia Pacific , Virus Inactivation Plasma Transfusion Filters , Leukocyte Removal Filters , Sterile Infusion Sets , Liquid Medicine Filter , Plasmapheresis Sets , Centrifuge Apparatus , Lightproof Infusion Sets , Ceru Current Report , Cerus Corporation And Shandong Zhongbaokang Medical Implements Partner To Establish Joint Venture In China , ஒன்றுபட்டது மாநிலங்களில் , பாஸ்கல் மெயிலார்ட் , பரிமாற்றம் தரகு , சாண்டோங் மாகாணம் , ஆசியா பெஸிஃபிக் ,